Medtronic Plc Hits New 52-Week Low at USD 73.68

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 73.68 as of May 29, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 11.22%, contrasting sharply with the S&P 500's gain of 28.21% during the same period. The company, with a market capitalization of USD 113,290 million, maintains a price-to-earnings (P/E) ratio of 20.00. Medtronic's dividend yield stands at 3.20%, reflecting its commitment to returning value to shareholders. Despite a relatively low debt-to-equity ratio of 0.43, the company has faced challenges in achieving robust long-term growth, evidenced by an operating profit growth rate of just 9.68% over the past five years. In terms of financial health, Medtronic reported its highest operating cash flow of USD 7,146 million in July, alongside a return on capital employed (ROCE) of 9.72%. The stock is currently trading at a discount compared to its peers, with institutional holdings at a notable 86.93%, indicating strong confidence from larger investors.